Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$49.99 ▼ -1.43
(-2.78%)
MKT CAP: $4.83B • VOL: 1.03M
52W L $44 52W H $63
CRSP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.5M | $37.3M | $371.2M |
| YoY Revenue Growth % | -90.6% | -89.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$664.6M | -$466.6M | -$222.5M |
| Operating Margin % | -18933.6% | -1250.4% | -60.0% |
| Net Income (GAAP) | -$581.6M | -$366.3M | -$153.6M |
| EBITDA (Normalized) | -$663.8M | -$465.0M | -$209.2M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$345.0M | -$142.8M | -$260.4M |
| Capital Expenditures (CapEx) | $914.0K | $1.9M | $16.7M |
| Free Cash Flow (FCF) | -$345.9M | -$144.7M | -$277.1M |
| FCF Margin % | -9855.5% | -387.7% | -74.6% |
| Return on Invested Capital (ROIC %) | -30.4% | -20.8% | -10.1% |
| Cash & Short-Term Equivalents | $347.6M | $298.3M | — |
| Total Debt (Short + Long Term) | $154.5M | $139.5M | $675.2M |
| Total Stockholders' Equity | $1.92B | $1.93B | $1.39B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRSP.